Drug Profile
Research programme: vascular disease therapy - Progen Pharmaceuticals
Latest Information Update: 24 Jul 2008
Price :
$50
*
At a glance
- Originator Cellgate
- Developer Progen Pharmaceuticals Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular restenosis
Most Recent Events
- 24 Jul 2008 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)
- 09 Aug 2007 Preclinical trials in Vascular restenosis in USA (unspecified route)